Showing results (1-10 of 123) with videos related to
Sort By:
Pageof 13
Expert Opinion on Investigational Drugs|August 17, 2010
Novel integrase inhibitors for HIVNicole Prada, Martin MarkowitzJournal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2015
Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variantHiroshi Mohri, Nicole Prada, Martin MarkowitzAntimicrobial Agents and Chemotherapy|August 5, 2009
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitorsAndrea Low, Nicole Prada, Michael Topper, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2014
A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individualsMartin Markowitz, Teresa H Evering, Donald Garmon, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical courseNicole Prada, Brandi Davis, Patrick Jean-Pierre, et al.Expert Opinion on Investigational Drugs|October 31, 2003
Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infectionSaurabh Mehandru, Martin MarkowitzCurrent HIV/AIDS Reports|March 15, 2012
Should we treat acute HIV infection?Meagan O'Brien, Martin MarkowitzThe AIDS Reader|August 29, 2006
Predictors of response to highly active antiretroviral therapyAndrea Low, Martin MarkowitzCurrent Opinion in Investigational Drugs (London, England : 2000)|September 8, 2006
Transmitted multidrug resistant HIV-1: new and investigational therapeutic approachesAnita Shet, Martin MarkowitzCurrent Opinion in HIV and AIDS|February 21, 2015
Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infectionCraig Pace, Martin MarkowitzPageof 13